Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever.
12 patients suffering from grass pollen hay fever were treated for 14 weeks pre- and co-seasonally by intranasal self-administration of an aqueous solution of a glutaraldehyde-treated timothy grass pollen allergen. These patients had a statistically significant decrease in nasal symptom scores during the grass pollen peak period and in nasal challenge end-point titre after the season compared to placebo-treated patients. No significant effect was seen on the eye symptoms. 1 patient withdrew from the trial as a consequence of too strong local nasal reactions during treatment. Most other patients treated with active material reported mild local reactions during the first minutes after administration of the nasal spray. In the actively treated group a significant increase in serum and nasal secretion of grass pollen specific IgE, IgG and IgA antibodies was obtained during the treatment. In contrast, in the placebo group a significant increase in IgE antibody levels in serum and secretion occurred during the pollen season. The reduction in symptoms and increase in antibody production together with the simplicity of the procedure makes this approach to immunotherapy attractive.
D000447:Aldehydes / Q000494:pharmacology*; D000485:Allergens; D002457:Cell Extracts / Q000008:administration & dosage* / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D005976:Glutaral / Q000494:pharmacology*; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D009299:Nasal Provocation Tests; D010919:Placebos; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy*; D014020:Tissue Extracts / Q000008:administration & dosage*
D000447:Aldehydes; D000485:Allergens; D002457:Cell Extracts; D010919:Placebos; D014020:Tissue Extracts; D007073:Immunoglobulin E; D005976:Glutaral